Background: Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin
lymphoma which is heterogeneous both clinically and morphologically. Over the past decades, significant advances
have been made in the understanding of the molecular genesis, leading to the identification of multiple
pathways and molecules that can be targeted for clinical benefit.
Objective: The current review aims to present a brief overview of signal pathways of DLBCL, which mainly
focus on B-cell antigen Receptor (BCR), Nuclear Factor-κB (NF-κB), Phosphatidylinositol-3-Kinase (PI3K) –
protein kinase B (Akt) – mammalian Target of Rapamycin (mTOR), Janus Kinase (JAK) – Signal Transducer
and Activator (STAT), Wnt/β-catenin, and P53 pathways.
Methods: Activation of signal pathways may contribute to the generation, development, chemotherapy sensitivity
of DLBCL, and expression of pathway molecules is associated with the prognosis of DLBCL. Some agents
targeting these pathways have been proved effective and relevant clinical trials are in progress. These agents
used single or combined with chemotherapy/each other might raise the possibility of improving clinical outcomes
Conclusion: This review presents several signal pathways of DLBCL and targeted agents had a tendency to
improve the curative effect, especially in high-risk or relapsed/refractory DLBCL.